Management of persistent AML at day 14

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Persistence of acute myeloid leukemia (AML) post-treatment is common.
• Early assessment of residual disease is crucial for prognosis.

Purpose of the Study:

• To discuss the prognostic significance of persistent AML.
• To compare morphology and multiparameter flow cytometry (MPFC) for assessing persistent AML.
• To review therapeutic options for persistent AML.

Main Methods:

• Discussion of prognostic significance.
• Comparative analysis of diagnostic methods (morphology vs. MPFC).
• Review of treatment strategies for persistent AML.

Main Results:

• Persistent AML in the first post-treatment marrow has prognostic implications.
• MPFC may offer advantages over morphology in detecting minimal residual disease.
• Several therapeutic strategies exist, including repeating induction chemotherapy, switching to high-dose cytarabine (HiDAC), or allogeneic hematopoietic cell transplantation (HCT).

Conclusions:

• Early detection of persistent AML is vital.
• The choice of therapy depends on disease status, patient factors, and treatment goals.
• Further research may refine optimal management strategies for persistent AML.